This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

Let's collaborate Boehringer Ingelheim

ESMO-Asia, Singapore 22-24 November 2019

Activity of afatinib in patients with NSCLC harboring uncommon EGFR mutations: pooled analysis of three large Phase IIIb trials

Antonio Passaro, Filippo de Marinis, Haiyan Tu, Konstantin K. Laktionov, Jifeng Feng, Artem Poltoratskiy, Jun Zhao, Eng-Huat Tan, Maya Gottfried, Victor Lee, Dariusz Kowalski, Cheng-Ta Yang, BJ Srinivasa, Laura Clementi, Wenbo Tang, Dennis Chin-Lun Huang, Agnieszka Cseh, Keunchil Park, Caicun Zhou, Yi-Long Wu

1200.193_uncommon_mutations_esmo_asia.jpg

Related Materials

Learn more about the science behind this poster in the videos, papers and other materials below.

Related Content

Lux-Lung 7 clinical trial summary

LUX-Lung 3 clinical trial summary

LUX-lung 6 clinical trial summary

NSCLC additional analyses and real-world evidence

RELATED INFORMATION

Afatinib

Afatinib (GIOTRIF®) as monotherapy is approved for the treatment of EGFR TKI-naïve adult patients with locally advanced or metastatic NSCLC with activating EGFR mutation(s); and locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy

About afatinib

A detailed look at afatinib’s mechanism of action and the ErbB Family of receptors that are targeted by afatinib
Back to top

FOR HEALTHCARE PROFESSIONALS ONLY

image